Clinical trial
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention
Abstract
This is a rater-blinded, randomized controlled trial. All patients will receive esketamine for treatment of Major Depression with Suicidal Ideation (MDSI). Subjects will be randomized (1:1) to receive CBT (computer-assisted) or TAU alone following esketamine.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
This study's objects
Directly linked records, matched by DOI, trial reference, or registry, not just topic.
Related research
ArticleKetamine
Pharmacologic Approaches to Suicide Prevention.
ArticleKetamine
Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.
ArticleKetamine